Newspaper icon
The latest issue of Financial Standard now available as an e-newspaper
READ NOW

Search Results

Showing 1 - 2 of 2 results for "Aflibercept Study"

Regal writes off Opthea, FUM takes 8% hit

KARREN VERGARA  |  THURSDAY, 10 APR 2025
... On March 31, ASX-listed Opthea announced it ceased the two major trials: COAST (Combination of OPT-302 with Aflibercept Study) and second Phase 3 trial ShORe (Study of OPT-302 in combination with Ranibizumab) in patients with wet AMD. "As previously ...

Regal slashes holdings in Opthea over insolvency concerns

KARREN VERGARA  |  TUESDAY, 25 MAR 2025
... listed on the ASX and Nasdaq, announced overnight that its phase three clinical trial Combination OPT-302 with Aflibercept Study (COAST) in patients with wet age-related macular degeneration failed. This triggered a repayment event to investors that ...
PAGE:
1